Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.53 |
| ▸ | RET | P07949 | 12/20 | 0.50 |
| ▸ | KDR | P35968 | 9/20 | 0.50 |
| ▸ | KIF5B | P33176 | 9/20 | 0.50 |
| ▸ | JAK3 | P52333 | 3/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | STK10 | O94804 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.46 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801726 | 1.00 | EGFR (0.53) | EGFRRETKDRKIF5BJAK3 | |
| Hydrochloric Acid SCHEMBL28006468 | 0.98 | EGFR (0.52) | EGFRRETKDRKIF5BJAK3 | |
| SCHEMBL7802744 | 0.93 | EGFR (0.53) | EGFRRETKDRKIF5BJAK3 | |
| SCHEMBL2476964 | 0.89 | RET (0.55) | EGFRRETKDRKIF5BJAK3 | |
| Piperidine SCHEMBL4197120 | 0.87 | EGFR (0.44) | EGFRRETKDRKIF5BJAK3 | |
| SCHEMBL12447316 | 0.84 | EGFR (0.52) | EGFRRETKDRKIF5BJAK3 | |
| SCHEMBL16016669 | 0.84 | RET (0.47) | EGFRRETKDRKIF5BJAK3 | |
| SCHEMBL20813476 | 0.84 | EGFR (0.52) | EGFRRETKDRKIF5BJAK3 | |
| SCHEMBL10945990 | 0.83 | EGFR (0.52) | EGFRRETKDRKIF5BJAK3 | |
| SCHEMBL20355452 | 0.83 | JAK3 (0.51) | EGFRRETKDRKIF5BJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110590683-B | Preparation method of intermediate of targeting drug AZD3759 | 山东四环药业股份有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-110590683-A | Preparation method of intermediate of targeting drug AZD3759 | 山东四环药业股份有限公司 | 2019-12-20 | — | — | CN | claimed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| CN-110590683-B | Preparation method of intermediate of targeting drug AZD3759 | 山东四环药业股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-110590683-B | Preparation method of intermediate of targeting drug AZD3759 | 山东四环药业股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-113307797-B | Polysubstituted quinazoline compound and application thereof | 江南大学 | 2022-08-09 | — | — | CN | disclosed |
| EP-3342770-B1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2022-03-30 | — | — | EP | disclosed |
| CN-113307797-A | Polysubstituted quinazoline compound and application thereof | 江南大学 | 2021-08-27 | — | — | CN | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1567506-A4 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA INC (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1567506-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | Array Biopharma, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2004046101-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | EGFR 2/4885RET 113/4885KDR 241/4885 |
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ERBB2, GRB2, EGFR | EGFR 3/4885RET 97/4885KDR 141/4885 |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | EGFR, ERBB2, ERBB3 | EGFR 1/4885RET 12/4885KDR 60/4885 |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | EGFR 2/4885RET 113/4885KDR 241/4885 |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ERBB2, GRB2, EGFR | EGFR 3/4885RET 97/4885KDR 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.